Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

Annals of Hematology

Volumn 82, Issue 5, 2003, Pages 284-289

  Kreuzer, Karl Anton ^a   le Coutre, P ^a   Landt, O ^b   Na, I K ^a   Schwarz, M ^a   Schultheis, K ^a   Hochhaus, A ^c   Dorken B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TIB MOLBIOL   (Germany)

^c MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Chronic myeloid leukemia; Imatinib; PCR; Peptide nucleic acid; Resistance

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; GLUTAMIC ACID; GLYCINE; HISTIDINE; IMATINIB; ISOLEUCINE; LYSINE; PEPTIDE NUCLEIC ACID; THREONINE; TYROSINE;

ADULT; AGED; ARTICLE; CELL CLONE; CHEEK MUCOSA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FLUORESCENCE HYBRIDIZATION PROBE ASSAY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MOLECULAR EVOLUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RISK ASSESSMENT; SAFETY; SENSITIVITY ANALYSIS; WILD TYPE;

EID: 0038514851     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0644-y     Document Type: Article

References (22)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nature Med 2:561-566
2. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163-168
3. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C (2000) Induction of resistance to the abelson inhibitor imatinib in human leukemic cells through gene amplification. Blood 95:1758-1766
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293:876-880
5. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a
6. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a
7. von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487-491
8. Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J, Sawyers CL (2001) Resistance to Gleevec: sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo- resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Blood 98:770a
9. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475
10. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP (2002) Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862
11. Kreil S, Müller MC, Lahaye T, La Rosée P, Corbin AS, Schoch C, Cross NCP, Berger U, Rieder H, Druker BJ, Gschaidmeier H, Hehlmann R, Hochhaus A (2001) Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood 98:435a
12. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125
13. Gambacorti-Passerini C, Mologni L, Bertazzoli C, le Coutre P, Marchesi E, Grignani F, Nielsen PE (1996) In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. Blood 1411-1417
14. Ørum H, Nielsen PE, Egholm M, Berg RH, Burchardt O, Stanley C (1993) Single base pair mutation analysis by PNA directed PCR-clamping. Nucleic Acids Res 21:5332-5336
15. Landt O, Lass U, Wallen M, Hänfler J (2002) One-step real-time detection of minimal amounts of single-base mutated alleles and their quantification using PNA-mediated PCR-clamping and hybridization probes. Nucleic Acids Res, in press
16. Kreuzer KA, Lass U, Bohn A, Landt O, Siegert W, Huhn D, Schmidt CA (1999) LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 59:3171-3174
17. Kreuzer KA, Lass U, Landt O, Nitsche A, Ellerbrok H, Pauli G, Laser J, Huhn D, Schmidt CA (1999) Highly sensitive and specific fluorescence RT-PCR assay for the pseudogene free detection of beta-actin transcripts as quantitative reference. Clin Chem 45:297-300
18. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
19. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-1937
20. Kreuzer KA, Lass U, Nagel S, Ellerbrok H, Pauli G, Pawlaczyk-Peter B, Siegert W, Huhn D, Schmidt CA (2000) Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples of chronic myelogenous leukemia patients. Int J Cancer 86:741-746
21. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lay JL, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018
22. le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt C, Schwarz M, Müller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA (2002) Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 28:75-85